

SCOREFLEX® NC TAIWAN LAUNCH

29 June - 2 July 2026 | Taiwan

Introduction

To support the official launch of Scoreflex® NC in Taiwan, OrbusNeich's Global Marketing Manager Sharon Tan joined the local sales team for a series of academic exchanges, hospital visits, and educational seminars from 29 June to 2 July.

The initiative engaged leading interventional cardiologists and cath lab teams across Taiwan's premier medical centers, providing an opportunity to showcase the device's enhanced performance, gather clinical insights, and strengthen relationships with key opinion leaders (KOLs).



Launch Highlights

Through meetings at National Taiwan University Hospital Yunlin Branch, Taipei Veterans General Hospital (TVGH), Far Eastern Memorial Hospital, MacKay Memorial Hospital, Changhua Christian Hospital, National Taiwan University Hospital, and Taichung Armed Forces General Hospital, the team facilitated in-depth discussions on the clinical applications and positioning of Scoreflex® NC.

Key discussion topics were:

- **Clinical positioning of scoring balloons based on SCAI Guidelines and TSCI Expert Consensus**
- **Differentiation between standard NC balloons and Scoreflex® NC**
- **Lesion selection and sizing strategies for scoring balloon procedures**
- **Safety considerations and best practices for lesion preparation**

The engagements also generated significant interest in OrbusNeich's future portfolio additions, including Scoreflex® TRIO and eucalimus™.



Dr. Shao-Sung Huang of TVGH, who had utilized Scoreflex® NC in a challenging case shortly before meeting with the team, reported that the balloon maintained excellent deliverability and crossing performance despite undergoing more than ten inflation-deflation cycles during the procedure.

According to Dr. Huang, the device navigated a severely stenosed lesion smoothly throughout the case, leaving a strong impression regarding its durability and structural integrity. This positive real-world experience provided compelling early clinical validation of the product's performance enhancements.



The Taiwan launch successfully introduced Scoreflex® NC to key stakeholders while generating valuable clinical feedback and strong physician endorsement. Positive real-world experiences, meaningful academic exchanges, and growing awareness of OrbusNeich's broader portfolio position the company well for continued adoption and expansion within Taiwan's complex PCI market.